Brief: Metis Techbio Enters Strategic Collaboration With Lilly
Mon 11:20
BRIEF-Metis Techbio Enters Strategic Collaboration With Lilly Oct 19 (Reuters) - Metis TechBio Co., Ltd. 7666.HK:
METIS TECHBIO ENTERED STRATEGIC COLLABORATION WITH LILLY
COLLABORATION TO ADVANCE NEXT-GENERATION TISSUE-SPECIFIC LNP DELIVERY TECHNOLOGIES
ELIGIBLE FOR UPFRONT PAYMENT AND UP TO $1.10 BLN IN MILESTONE PAYMENTS
ELIGIBLE FOR SINGLE-DIGIT TIERED ROYALTIES ON ANNUAL NET SALES
Further company coverage: 7666.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Metis TechBio
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
HK-listed Metis TechBio climbs on deal with Eli Lilly
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Metis TechBio, Eli Lilly strike drug-delivery deal worth up to $1.1 billion (updated)
Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech